Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick-Pascal Strunz

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Zeitschrift Fur Rheumatologie|September 23, 2025
[Renewed increase in new Janus kinase inhibitor prescriptions : Analysis of the German RHADAR registry]Patrick-Pascal Strunz, Linus Maximilian Risser, Matthias Englbrecht, et al.
Frontiers in Immunology|September 6, 2024
Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective studyPatrick-Pascal Strunz, Linus Maximilian Risser, Matthias Englbrecht, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Whole-Body [<sup>18</sup>F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic DiseaseMatthias Fröhlich, Sebastian Serfling, Takahiro Higuchi, et al.
Therapeutic Advances in Musculoskeletal Disease|June 29, 2026
Association of an app-based intervention with improvements in mobility, trunk muscle strength and patient-reported disease activity in axial spondyloarthritis: a 24-week pre-post studyPatrick-Pascal Strunz, Marc Schmalzing, Amelie Wüst, et al.
Frontiers in Immunology|June 7, 2024
Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR databasePatrick-Pascal Strunz, Matthias Englbrecht, Linus Maximilian Risser, et al.
Rheumatology International|August 13, 2024
Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR networkPatrick-Pascal Strunz, Matthias Englbrecht, Linus Maximilian Risser, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Zeitschrift Fur Rheumatologie|September 23, 2025
[Renewed increase in new Janus kinase inhibitor prescriptions : Analysis of the German RHADAR registry]Patrick-Pascal Strunz, Linus Maximilian Risser, Matthias Englbrecht, et al.
Frontiers in Immunology|September 6, 2024
Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective studyPatrick-Pascal Strunz, Linus Maximilian Risser, Matthias Englbrecht, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Whole-Body [<sup>18</sup>F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic DiseaseMatthias Fröhlich, Sebastian Serfling, Takahiro Higuchi, et al.
Therapeutic Advances in Musculoskeletal Disease|June 29, 2026
Association of an app-based intervention with improvements in mobility, trunk muscle strength and patient-reported disease activity in axial spondyloarthritis: a 24-week pre-post studyPatrick-Pascal Strunz, Marc Schmalzing, Amelie Wüst, et al.
Frontiers in Immunology|June 7, 2024
Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR databasePatrick-Pascal Strunz, Matthias Englbrecht, Linus Maximilian Risser, et al.
Rheumatology International|August 13, 2024
Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR networkPatrick-Pascal Strunz, Matthias Englbrecht, Linus Maximilian Risser, et al.
Pageof 5